GLUE Monte Rosa Therapeutics, Inc.

1d ago, source: Seeking Alpha

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to ...

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

1mon ago, source: Stockhouse

Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and financial ...

Monte Rosa Therapeutics Inc (GLUE) Reports Full Year and Q4 2023 Financial Results

1mon ago, source: Yahoo Finance

Warning! GuruFocus has detected 2 Warning Signs with GLUE. On March 14, 2024, Monte Rosa Therapeutics Inc (NASDAQ:GLUE) released its 8-K filing, detailing the company's financial results for the ...

Monte Rosa Therapeutics: Q4 Earnings Snapshot

1mon ago, source: The Washington Post

BOSTON — BOSTON — Monte Rosa Therapeutics Inc. (GLUE) on Thursday reported a loss of $33.3 million in its fourth quarter. The Boston-based company said it had a loss of 58 cents per share.

Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

1mon ago, source: Finanznachrichten

Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and ...

Monte Rosa Therapeutics Inc GLUE

2d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update

1mon ago, source: ADVFN

Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and ...

Monte Rosa Therapeutics Inc

3d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Monte Rosa Therapeutics Inc.

22d ago, source: Wall Street Journal

1 Day GLUE -17.02% DJIA 0.16% Russell 2K 0.34% Health Care/Life Sciences -0.15% ...

Monte Rosa Therapeutics Inc (GLUE)

5d ago, source: Investing

2024 Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced a novel ...